Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 16/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.44 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.38 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.36 |
| ▸ | FBP1 | P09467 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4100419 | 0.89 | TLR7 (0.43) | TLR7FGFR1SLC22A6NUDT1 | |
| SCHEMBL14311779 | 0.88 | FGFR1 (0.46) | TLR7FGFR1SLC22A6HPRT1FBP1 | |
| SCHEMBL13726716 | 0.88 | TLR7 (0.43) | TLR7FGFR1SLC22A6NUDT1 | |
| SCHEMBL3995288 | 0.88 | TLR7 (0.47) | TLR7NUDT1 | |
| SCHEMBL3920579 | 0.86 | TLR7 (0.45) | TLR7NUDT1FBP1 | |
| SCHEMBL13728126 | 0.85 | TLR7 (0.48) | TLR7NUDT1 | |
| SCHEMBL4105942 | 0.85 | TLR7 (0.43) | TLR7NUDT1HPRT1 | |
| SCHEMBL4102158 | 0.85 | TLR7 (0.41) | TLR7FGFR1SLC22A6NUDT1FBP1 | |
| SCHEMBL19633361 | 0.83 | TLR7 (0.49) | TLR7NUDT1 | |
| SCHEMBL4105905 | 0.82 | CYP3A4 (0.44) | TLR7NUDT1HPRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310469-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION WITH TOLL-LIKE-RECEPTOR AGONISTS | Accencio LLC | 2023-10-05 | — | — | US | disclosed |
| US-20230310469-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION WITH TOLL-LIKE-RECEPTOR AGONISTS | Accencio LLC | 2023-10-05 | — | — | US | disclosed |
| EP-2038290-B1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | GILEAD SCIENCES INC (US) | 2013-09-04 | — | — | EP | disclosed |
| EP-2038290-B1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | GILEAD SCIENCES INC (US) | 2013-09-04 | — | — | EP | disclosed |
| US-8338593-B2 | Agonists; Treatment of Hepatitis C virus; phosphinate-substituted purine derivatives | GILEAD SCIENCES, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-8338593-B2 | Agonists; Treatment of Hepatitis C virus; phosphinate-substituted purine derivatives | GILEAD SCIENCES, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-8338593-B2 | Agonists; Treatment of Hepatitis C virus; phosphinate-substituted purine derivatives | GILEAD SCIENCES, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20090202484-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | GILEAD SCIENCES, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20090202484-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | GILEAD SCIENCES, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20090202484-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | GILEAD SCIENCES, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| EP-2038290-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | Gilead Sciences, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| WO-2008005555-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | GILEAD SCIENCES, INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| US-20080008682-A1 | Modulators of toll-like receptor 7 | GILEAD SCIENCES, INC. | 2008-01-10 | — | — | US | disclosed |
| WO-2008005555-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | GILEAD SCIENCES, INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| US-20080008682-A1 | Modulators of toll-like receptor 7 | GILEAD SCIENCES, INC. | 2008-01-10 | — | — | US | disclosed |
| US-20080008682-A1 | Modulators of toll-like receptor 7 | GILEAD SCIENCES, INC. | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080008682-A1 | Modulators of toll-like receptor 7 | TLR7, TLR6, TLR3 | TLR7 1/4885FGFR1 919/4885SLC22A6 1725/4885 |
| US-20230310469-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION WITH TOLL-LIKE-RECEPTOR AGONISTS | TLR3, TLR7, TLR8 | TLR7 2/4885FGFR1 1067/4885SLC22A6 3460/4885 |
| US-20090202484-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | TLR7, TLR6, TLR3 | TLR7 1/4885FGFR1 923/4885SLC22A6 1647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.